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Abstract
The APOBEC3 proteins form a multigene family of cytidine deaminases with inhibitory activity against viruses and
retrotransposons. In contrast to APOBEC3G (A3G), APOBEC3A (A3A) has no effect on lentiviruses but dramatically inhibits
replication of the parvovirus adeno-associated virus (AAV). To study the contribution of deaminase activity to the antiviral
activity of A3A, we performed a comprehensive mutational analysis of A3A. By mutation of non-conserved residues, we
found that regions outside of the catalytic active site contribute to both deaminase and antiviral activities. Using A3A point
mutants and A3A/A3G chimeras, we show that deaminase activity is not required for inhibition of recombinant AAV
production. We also found that deaminase-deficient A3A mutants block replication of both wild-type AAV and the
autonomous parvovirus minute virus of mice (MVM). In addition, we identify specific residues of A3A that confer activity
against AAV when substituted into A3G. In summary, our results demonstrate that deaminase activity is not necessary for
the antiviral activity of A3A against parvoviruses.
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Introduction
Eukaryotes have evolved numerous innate immune defenses
against invading pathogens. The apolipoprotein B mRNA-editing
catalytic polypeptide-like 3 (APOBEC3) proteins comprise a family of
seven cytidine deaminases [1–4] that may each form distinct intrinsic
barriers to endogenous retrotransposons and invading viruses [5–7].
The most characterized member of the family is APOBEC3G (A3G),
which restricts Vif-deficient human immunodeficiency virus 1 (HIV-
1) [8–11]. In addition to HIV-1, the APOBEC3 proteins inhibit a
diverse array of viruses including simian immunodeficiency virus
(SIV), human T cell leukemia virus 1 (HTLV1), murine leukemia
virus (MLV),mouse mammarytumor virus (MMTV), and hepatitis B
virus (HBV) [6,7,10–13]. Interestingly, human APOBEC3A (A3A)
lacks activity against retroviruses but dramatically inhibits replication
of the parvovirus adeno-associated virus (AAV) [14]. The molecular
mechanisms that govern specificity of APOBEC3 antiviral activity
are not yet fully understood.
The APOBEC3 proteins share structural and functional
features with zinc-dependent deaminases and possess cytidine
deaminase activity [1,4]. The cytidine deaminase domains (CDDs)
of APOBEC3 proteins contain an active site with the conserved
consensus motif H-X-E-X23–28-P-C-X2–4-C (where X is any
amino acid). It has been proposed that the histidine and the two
cysteine residues coordinate a Zn
2+ ion, while the glutamic acid
residue serves an essential role in catalysis as a proton shuttle [15–
18]. APOBEC3 proteins contain either a single CDD (A3A, A3C
and A3H) or two tandem CDDs (A3B, A3D/E, A3F and A3G). In
the case of A3G, both domains contain an intact active site
consensus sequence motif but only CDD2 appears to be
catalytically active, while CDD1 is responsible for interaction
with the HIV nucleocapsid proteins and packaging [19–23].
Sequence alignment shows that A3A is highly homologous to the
C-terminus of A3B and A3G proteins [2].
The mechanism of the antiviral activity of APOBEC3 proteins
against retroviruses has been studied extensively [5,6,24].
APOBEC3 proteins are incorporated into virus particles, and
encapsidation is mediated via interactions with Gag, viral RNA
and cellular RNAs [19,22,23,25–32]. Encapsidated A3G is
delivered into target cells where it deaminates dC to dU on newly
synthesized minus strand cDNAs during the process of reverse
transcription [9–11,33–35]. Deaminated genomes can be degrad-
ed by the action of the cellular base excision repair machinery
[36], although recent reports suggest that uracil-DNA glycosylase
2 (UNG2) is not required for the A3G antiviral function [37,38].
In addition, hypermutated proviruses will contain sequence
changes that inactivate the virus by generating alternate splicing,
premature translation, and nonfunctional proteins [39].
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the antiviral activity of APOBEC3 proteins remains controversial
[39]. APOBEC3 chimeric proteins and catalytically inactive
mutants demonstrate that inhibition of HIV-1 can be achieved
by A3G that lacks deaminase activity [40–42]. A3G can inhibit
lentivirus reverse transcriptase (RT) and prevent accumulation of
reverse transcripts and viral cDNA in target cells in a deamination-
independent manner [35,42–44]. Additionally, subsequent steps of
viral integration have been shown to be affected by APOBEC3
proteins [37,45]. The idea of deaminase-independent antiviral
activity has been challenged by others who have argued that
cytosine deamination is required for efficient inhibition of
retroelements at low levels of APOBEC3 expression [38,46,47].
In the case of HBV, the mechanism for inhibition by APOBEC3
proteins is also controversial but has been suggested to be
deaminase-independent due to infrequent editing, and may be
caused by blocking reverse transcription and expression of HBV
antigens [12,48,49].
Although it lacks activity against retroviruses, A3A is a potent
inhibitor of both parvovirus and the human transposon LINE-1
[14,50,51]. Parvoviruses are small eukaryotic viruses that infect
humans and a variety of other animal species [52]. The parvovirus
genome consists of a linear single-stranded DNA (ssDNA)
molecule approximately 4.5 kb in length, with hairpin structures
at both ends that function as origins for viral DNA replication.
The genome contains two major ORFs that encode the
nonstructural replication proteins (NS or Rep) and the structural
capsid proteins (Cap). The family is divided into autonomous
parvoviruses and dependoviruses, which require a helper virus for
efficient replication and progeny production. The minute virus of
mice (MVM) is an autonomous parvovirus while adeno-associated
virus (AAV) is a dependovirus that uses adenovirus as a helper
virus. In our previous studies we found that despite the absence of
detectable AAV editing, mutations in conserved active site residues
of A3A abrogated the antiviral activity against AAV [14].
A3A inhibition of parvovirus provides an attractive system in
which to decipher the relative contribution of deamination and
deaminase-independent mechanisms to antiviral activity. Unlike
the other viruses known to be inhibited by APOBEC3 proteins,
the parvoviruses replicate exclusively in the nucleus, do not pass
through RNA intermediates, do not have a reverse transcription
step in their replication schemes, and use DNA hairpins for
priming replication [52]. Moreover, A3A is a simplified system for
probing APOBEC3 functions because it has a single CDD and is
not restricted to a specific subcellular compartment [2,14].
To ascertain whether deaminase activity is required for
inhibition of parvovirus replication, and to understand the
functional significance of amino acid divergence between A3A
and A3G, we analyzed the properties of a panel of A3A point
mutants and A3A/A3G chimeras. The proteins were tested for
deaminase activity in vitro and for antiviral activity in rAAV
production assays. We identify mutants that lack deaminase
activity but retain the antiviral effect, supporting the idea of a
deamination-independent mechanism. In addition to AAV, we
show that A3A inhibits DNA replication of the autonomous
parvovirus MVM. Chimeric A3A/A3G proteins generated by
exchanging divergent sequences demonstrate loss-of-function for
A3A and gain-of-function for A3G. Our mutants also reveal
residues in the linker and pseudoactive site domains that are
important for deamination, target specificity and antiviral activities
of A3A. Together, these studies reveal domains of A3A that are
responsible for its distinct antiviral activity and suggest that A3A
can inhibit parvoviruses through a mechanism separate from its
function as a cytidine deaminase.
Results
Inhibition of rAAV Production Is Not Dependent Upon
the Deaminase Activity of A3A
We previously showed that A3A antiviral activity was
dependent on the integrity of conserved amino acids in the active
site that are responsible for proton shuttling and zinc coordination
[14]. These results suggested that the catalytic domain of A3A
must be intact for antiviral activity against AAV. To extend these
studies, we generated additional point mutations at conserved
residues (F75 and F95) previously shown to be required for
deaminase activity of APOBEC1 [16,53]. We also mutated the
99SPC101 residues to AAA (SPC) in the active site domain of A3A
[50]. The position of these mutants is indicated in Figure 1A.
First, we determined the cellular localization of the mutant
proteins in transfected U2OS and HeLa cells (Figure 1B and data
not shown). Wild-type A3A was located throughout the cell, while
A3G was predominantly cytoplasmic (Figure 1B). Most of the A3A
mutants displayed cellular localization patterns similar to wild-type
protein. The double mutant FF7595LL showed a nuclear punctate
pattern (also observed in some cells transfected with E72Q and
SPC), which might reflect misfolded protein.
We next measured the catalytic activity of the proteins using an in
vitro deamination assay. We previously demonstrated deaminase
activity for A3A packaged into HIV-1 virions [14]. To bypass the
requirement for packaging, we directly immunoprecipitated A3A
from lysates of transfected cells [47]. We further adapted the assay
to control for different expression levels by generating A3A by
coupled in vitro transcription/translation (IVT) using wheat germ
extract. An advantage of this method is that it allows assessment of
proteins that are unstable or difficult to express in cells, such as
FF7595LL and A3A truncations (Figure S1). Cytidine deaminase
activityoftheimmunoprecipitateswas measuredbyincubationwith
a radiolabeled deoxyoligonucleotide containing a single deoxycyti-
Author Summary
The APOBEC3 proteins constitute a family of seven cytidine
deaminases. Cytidine deaminases are editing enzymes able
to remove the amine group from cytidine in single-strand
DNA (ssDNA) and RNA, converting it to uracil. APOBEC3
proteins have potent antiviral activity against retroviruses,
retrotransposons, and DNA viruses. APOBEC3 generated
high interest because of the ability of APOBEC3G (A3G) to
inhibit HIV. APOBEC3A (A3A) is a member of the family
that inhibits the human parvovirus adeno-associated virus
(AAV) and the retrotransposon LINE-1. Parvoviruses are
simple ssDNA viruses that do not require a retrotranscrip-
tion step for their replication. In contrast to A3G, which is
predominantly cytoplasmic, A3A is located in both the
nucleus and cytoplasm. In addition, A3A consists of a
single cytidine deaminase catalytic domain, whereas A3G
has two. The dependence of the antiviral function on
deaminase activity is controversial. In this study, we
identify numerous A3A residues required for deaminase
and antiviral activities. We show that A3A not only inhibits
AAV but also the minute virus of mice (MVM). Importantly,
we demonstrate that A3A does not require its deaminase
activity to block the replication of both parvoviruses. Thus,
exploiting the simplicity of parvoviruses together with the
single-domain cytidine deaminase A3A, we are able to
demonstrate that cytidine deaminase activity is not
required for APOBEC3 mediated viral inhibition.
Deaminase-Independent APOBEC3A Antiviral Activity
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deaminase activity (Figure 1C) and demonstrated similar activity to
A3A produced by transfection (Figure S1). These results showed
that the IVT generated protein was catalytically active and also
suggestedthat A3A does notrequire a mammaliancellular co-factor
foritscatalyticactivity.Analysisofthe activesite mutantsintheIVT
system showed that, consistent with previous studies, mutants in
conserved active site amino acids (H70R, E72Q, C106S, and SPC)
had lost deaminase activity [14,50]. Although the F75 and F95
residues have both been shown to be required for APOBEC1
deaminase activity, the F95L mutant of A3A retained deaminase
activity in our analysis, while the F75L mutant was inactive.
The antiviral activity of A3A mutants was compared to wild-
type A3A and A3G by transfection of 293T cells in the
recombinant AAV (rAAV) production assay (Figure 1D). The
APOBEC3 expression vectors were cotransfected with plasmids
required for rAAV replication and packaging. The Rep and Cap
proteins were supplied in trans to allow replication of an AAV
vector and packaging of the ssDNA genome into virus particles. In
this study we employed rAAV expressing luciferase (rAAVLuc),
which allowed for quantitative assessment of virus production by
transduction of target cells. Immunoblotting confirmed that
proteins of the expected size were expressed (Figure 1D). Wild-
type A3A completely blocked rAAV production, as previously
reported [14]. In contrast, neither A3G nor the active site A3A
mutants H70R, E72Q, SPC and C106S inhibited rAAV
production. The F95L mutant that retains deaminase activity
was active against rAAV. Surprisingly, F75L also inhibited rAAV
despite its lack of deaminase activity in the in vitro assay. The F75L
protein is therefore a separation-of-function mutant of A3A that
facilitates analysis of the relative contribution of the deaminase-
dependent and -independent mechanisms to AAV inhibition. The
Figure 1. Deamination is not required for antiviral activity of A3A. (A) Schematic of A3A and active site mutants. Domains marked are the
cytidine deaminase domain (CDD), the linker (LINK), the pseudoactive site (PAS) and the hemagglutinin epitope tag (H). Active site residues
conserved among APOBEC3 proteins (H-X-E-X28-PC-X4-C) are indicated in bold. Asterisks indicate specific mutations generated for this study; F75 is
indicated with a red asterisk. (B) Immunofluorescence to detect HA-tagged APOBEC3 proteins (red) expressed by transfection in U2OS cells. (C) In
vitro assay for cytidine deaminase activity. Proteins were generated by IVT, immuno-precipitated by the HA epitope, and incubated with a
radiolabeled substrate (T28TCAT29). The deaminated molecules were cleaved by treatment with UDG followed by high pH, and the products were
resolved by PAGE (upper panel). Arrows indicate the substrate and deaminated product. The panel below shows an immunoblot to detect in vitro
translated proteins. (D) Inhibition of AAV. Production of rAAVLuc was assessed by transfection of 293T cells with AAV plasmids in the presence of
APOBEC3 expression constructs (1 mg). Production of rAAV was assessed by transduction of target cells and quantitation of luciferase activity.
Presented is the average of three independent experiments normalized to vector only control (mock). The panels below show immunoblots to detect
HA-tagged wild type and mutant A3A proteins in transfected 293T cell lysates. Ku86 served as a loading control.
doi:10.1371/journal.ppat.1000439.g001
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was poorly expressed and showed altered cellular distribution.
Together, these data demonstrate that deaminase activity is not
required for the anti-AAV effect of A3A.
A3A Inhibits Parvovirus Replication by a Deaminase-
Independent Mechanism
To exclude differences in AAV inhibition due to disparities in
protein expression levels, we compared the mutants F75L and
F95L with wild-type A3A over a dose-response (Figure 2A).
Immunoblotting revealed that expression levels of the mutants
F75L and F95L were approximately ten-fold lower than wild-type
A3A when equal amounts of DNA were transfected. However,
despite differences in the deamination ability of the mutants, they
displayed similar antiviral activity to wild-type A3A when
equivalent protein levels were compared. We tested the F75L
mutant against a panel of oligonucleotides that contained a
cytosine in each of the possible tri-nucleotide configurations, but
found no evidence of deamination above background levels on any
sequence (Figure S2A and Table S1). Therefore the lack of
detectable deaminase activity for F75L in vitro was not caused by
an altered target sequence preference. We also tested the
deaminase activity of A3A mutants in cell lysates by adapting
the quantitative fluorescence resonance energy transfer (FRET)
assay recently developed for A3G [54]. This FRET assay measures
cleavage of a target oligonucleotide dual-labeled with fluorophores
(Figure S2B). We observed dose-dependent deaminase activity
with increasing amounts of cell lysates from 293T cells transfected
with the A3A plasmid. Background levels of activity were obtained
with the defective mutants E72Q and C106S. F95L showed
deaminase activity in this assay, whereas F75L was not above
background (Figure S2B). This result supports the observations
from the in vitro deaminase assay and the conclusion that AAV is
inhibited in the absence of deamination.
In our previous studies of AAV production in the presence of
wild-type A3A, we found no detectable evidence of AAV sequence
changes but viral replication was inhibited [14]. To detect effects
of A3A on the accumulation of rAAV DNA, we used Southern
blotting of low molecular weight DNA extracted from the
transfected cells during rAAV production (Figure 2B). As controls,
we compared the A3A mutants to wild-type A3A and A3G.
Replicated rAAV DNA was detected by hybridization with a
luciferase probe. Although F75L was slightly less effective than
F95L, both mutants inhibited the accumulation of rAAV DNA
(Figure 2B), suggesting that inhibition of AAV replication is not
dependent on deamination.
To examine the effect of A3A and mutants on replication of
wild-type parvovirus genomes, we used two different viral systems.
AAV2 depends upon helper virus for replication, while MVM
replicates autonomously. First we used immunofluorescence to
assess the effect of APOBEC3 proteins in cells infected with AAV2
and adenovirus helper virus. As previously shown [14], replication
centers detected by staining for the viral Rep protein were present
in cells that expressed A3G but were absent in those with A3A
(Figure 3A). Advanced stage viral replication centers were detected
in cells expressing inactive mutants. In contrast, A3A mutants that
inhibited rAAV production (F75L and F95L) also blocked
formation of viral replication centers. These data demonstrate
that observations made with rAAV production also apply to
inhibition of wild-type AAV replication.
Replication of an infectious plasmid clone of MVM was also
dramatically inhibited by co-transfection of wild-type A3A, but not
Figure 2. A3A mutants inhibit AAV DNA replication. (A) Titration of wild-type and mutant A3A expression vectors in rAAVLuc production
assays. Production of rAAVLuc was assessed by transduction of target cells and quantitation of luciferase activity. Presented is the average of four
independent experiments normalized to vector alone control (mock). The panels below show immunoblots to detect HA-tagged wild-type and
mutant A3A proteins in transfected 293T cell lysates. (B) Southern blot detection of low molecular weight DNA extracted from 293T cells transfected
for rAAVLuc production in the presence of mock (1 mg) A3G (1 mg), A3A (1, 0.1, 0.01 and 0.001 mg) and mutant A3A expression vectors (1 mg). The
DNA was digested with Dpn-I, separated by gel electrophoresis, and hybridized with a radiolabeled luciferase probe.
doi:10.1371/journal.ppat.1000439.g002
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of an MVM genome bearing a large in-frame deletion within the
capsid gene, and therefore unable to generate the wild-type capsid
proteins necessary to produce single-stranded progeny DNA
(MVM-DBglII), was also inhibited by A3A (Figure 3B, lanes 4–
6). In separate experiments, the expression of the full spectrum of
MVM RNA and protein generated from a non-replicating full-
length MVM plasmid was not affected by expression of A3A (data
not shown), suggesting that A3A directly affects parvovirus
genome replication.
The Linker and Pseudoactive Domains of A3A Are
Required for Antiviral Activity
To identify further residues required for A3A antiviral activity,
we compared the sequence of A3A to the C-terminus of A3B and
A3G. Alignment of the amino acid sequences showed that A3A is
most closely related to A3B. Two main regions with variable
sequences (VS1 and VS2) differ from A3G (Figure 4). Using the
structure of the C-terminal domain of A3G as a template [55], we
predicted the secondary structure of A3A (Figure 4) and this
suggested that the VS1 would be located in the loop between the
b2 strand and the a1 helix, and that VS2 partially overlaps with
the a4 helix. To define regions of A3A responsible for the antiviral
activity against parvoviruses, we tested the contribution of the
linker and pseudoactive site subdomains [2]. We first generated
chimeric proteins between A3A and A3G (Figure 5A) joined at the
shared PmlI site. The N-terminus of A3A (residues 1–119) was
fused to the C-terminal PmlI fragment of A3G (residues 306–384)
to form the chimera A3ApmlA3G. The reciprocal chimera
A3GpmlA3A was also generated. We also assessed the activity of
the C-terminus of A3G (A3G-CT, residues M197 to N384) and a
fusion with A3A at the PmlI site (A3G-CTpmlA3A). Cellular
localization of the mutants was tested by immunofluorescence in
transfected cells (Figure S3A). We found that localization of the
chimeric proteins to the cytoplasm was determined by the N-
terminal domain of A3G as previously reported [51]. We also
measured the deaminase activity of chimeric proteins immuno-
precipitated from transfected cells in the in vitro assay with the
T28CCCGT28 deoxyoligonucleotide substrate (Figure 5B, upper
panel). Full-length A3A and A3G both produced robust
deamination, but all of the chimeras were less active. The mutants
were also tested for activity against rAAV in the transfection assay
(Figure 5C). Neither A3G nor A3G-CT had any inhibitory effect
against rAAV despite being expressed well in transfected cells.
Fusion of the linker and pseudoactive site subdomains of A3A onto
Figure 3. A3A inhibits AAV2 and MVM DNA replication. (A) Inhibition of wild-type AAV replication. U2OS cells were transfected with plasmids
for APOBEC3 proteins and then infected with AAV and adenovirus. HA-tagged APOBEC3 (red) and AAV Rep proteins (green) were detected by
immunofluorescence using specific antibodies. (B) Inhibition of wild-type MVM replication. Southern blot detection of low molecular weight DNA
extracted from A9 cells cotransfected with an infectious MVM clone together with APOBEC3A expression plasmids. The DNA was digested with Dpn-I,
separated by gel electrophoresis and hybridized with a radiolabeled MVM probe. Left line is a marker (M). Replicative intermediates of ssDNA (SS),
monomer (M), and dimer (D) are indicated to the right. Panel below shows immunoblots for APOBEC3 and the NS1 protein of MVM.
doi:10.1371/journal.ppat.1000439.g003
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(A3GpmlA3A and A3G-CTpmlA3A). The A3ApmlA3G chimera,
which possesses the linker and pseudoactive site of A3G fused onto
A3A, showed diminished antiviral activity. This reduction was
confirmed in a dose-response titration (Figure 5D). Together these
data suggest that the linker and pseudoactive site regions of A3A
are important for deamination and antiviral activity, but that these
domains are not sufficient to confer activity to A3G.
Careful inspection of the deaminase assay autoradiograms
(Figure 5B, upper panel) revealed that the deaminated products for
A3A and A3G have slightly different mobilities, which likely
reflects differences in deamination target specificity [14,33,56–59].
The deamination product for A3GpmlA3A migrated similarly to
that of A3A, suggesting it had gained the target site specificity of
A3A. To test this possibility, we analyzed the deaminase activity
on a deoxyoligonucleotide containing the specific A3A target
sequence TCA (Table S1). While A3A was highly active on the
TCA substrate, A3G was inactive (Figure 5B, middle panel).
Although the level of deamination by the A3GpmlA3A chimera
was less than that of A3A, this mutant was similarly active on both
substrates (Figure 5B, compare upper and middle panels). These
observations suggest that the region encompassing the linker and
pseudoactive site is involved in target site selection [56]. In our
assay the C-terminal fragment of A3G was inactive, although
recent studies reported that a similar fragment of A3G (residues
198–384) showed mutator activity in bacteria [17,60] and
deaminase activity in vitro [55]. However, these studies used
GST-tagged A3G-CT in the bacterial assays or purified
recombinant protein in their in vitro assays, while we have analyzed
protein from cell lysates. Furthermore, A3G-CT was shown to be
significantly less active than the full-length protein [55]. Our
results may also reflect differences in experimental conditions or
that protein produced by transfection may be less active due to
RNA inhibition or lack of dimerization.
Deaminase Activity Is Dispensable for Activity against
rAAV
Based on the analysis of chimeric proteins, we generated further
mutants in which non-conserved residues of A3A were substituted
with those from A3G (see Figure 4). Amino acids that differed
between the two proteins were changed throughout A3A
(Figure 6A). Most of the mutants consisted of A3A residues
replaced with the analogous A3G sequence. Two residues lacking
in A3G were deleted from A3A (DWG), and in another mutant
unique residues from A3G were inserted into A3A (EPWVR). The
two main variable regions that contain stretches of divergence
(VS1 and VS2 in Figure 4) were switched in two stages that
changed 3 or 4 residues at a time (Figure 6A). All mutants
displayed the same pattern of cellular localization as wild-type
A3A (Figure S3B). Mutant proteins were synthesized by IVT and
evaluated for deaminase activity in the in vitro assay (Figure 6B).
Mutants PT, MAK, and SK retained wild-type levels of activity.
The EPWVR and DWG mutants had diminished activity
compared to wild-type A3A. The chimeras in variable stretches
VS1 and VS2 lacked detectable deaminase activity. When these
mutants were included in the rAAV production assay, all of them
retained the ability to inhibit AAV (Figure 6C). The VS1 mutants
with diminished antiviral activity (GFLE and PHKHGFLE) were
also compared to wild-type A3A over a dose response (Figure S4).
When similar levels of protein were compared for their effect on
rAAV production, the VS1 mutants GFLE and PHKHGFLE
showed less activity than wild-type A3A (,75% inhibition
compared to ,95%) (Figure S4). This observation suggests that
the VS1 region in A3A contributes to the antiviral activity.
Together these data demonstrate that residues outside of the
putative enzymatic active site of A3A, in both the N-terminus and
C-terminus, are required for efficient deamination but that this
does not correlate with antiviral activity against parvovirus
replication.
Figure 4. Alignment of APOBEC3 amino acid sequences for A3A with the C-terminus of A3B and A3G. Residues exchanged in A3A are
boxed and the mutant designation is indicated above. The PmlI site and stretches of variable sequence VS1 and VS2 switched in the chimeras are also
indicated. The asterisks mark individual amino acid mutants, and the diamond indicates the start of A3G-CT (residues 197–384). Residue numbers are
indicated on the right side. Predicted secondary structure of A3A is indicated below the alignment with a-helices in black and stranded b-sheets in
grey. A3A secondary structure modeling was generated by Swiss-Model using the crystal structure of the C-terminal fragment of A3G (Protein Data
Bank accession number 3E1A) as template [77].
doi:10.1371/journal.ppat.1000439.g004
Deaminase-Independent APOBEC3A Antiviral Activity
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Analysis of the A3A mutants suggested that the two stretches of
residues divergent between A3A and A3G (VS1 and VS2) are
important for deamination, and may play a role in antiviral
function. Therefore, we determined whether the reciprocal switch
(where residues in A3G were substituted with the sequences from
A3A) would generate a gain-of-function (Figure 7A). Sequences
from A3A were incorporated into constructs that express the C-
terminal fragment of A3G which can localize in the nucleus
(Figure 7B). The mutant proteins were tested for their effect on
AAV in the virus production assay (Figure 7C). Proteins of the
expected size were expressed at similar levels. The C-terminal
fragment that contained the complete sequence from VS1 of A3A
(A3G-CT/KNLLCGFY) acquired significant inhibitory activity
against AAV. It was less active than wild-type A3A and reduced
rAAV production by approximately 50% when equal levels of
protein where compared (Figure S5). When incorporated into full-
length A3G, the VS1 region of A3A increased deamination in vitro,
whereas the VS2 sequences decreased activity (Figure S6).
Incorporation of the A3A sequences into full-length A3G did
Figure 5. Activity of A3A/A3G PmlI based chimeras. (A) Schematic of A3A (dark grey) and A3G (light grey). Domains marked are the cytidine
deaminase domains (CDD), the linker (LINK), the pseudoactive site (PAS), and the hemagglutinin epitope tag (H). Below are the chimeras generated at
the PmlI site. (B) In vitro assays for cytidine deaminase activity. Proteins were immunoprecipitated from transfected cells by the HA epitope and
incubated with the indicated radiolabeled substrate in UDG-dependent assays. The upper panel uses a substrate oligonucleotide with target
sequence CCCG, and the middle panel uses an oligonucleotide with the specific A3A target sequence TCA. The substrate and deaminated products
are indicated. The bottom panel shows an immunoblot to detect proteins in immunoprecipitates. A band corresponding to the light-chain IgG used
for immunoprecipitation is indicated (*). (C) Production of rAAV in the presence of APOBEC3 proteins. 293T cells were transfected with APOBEC3
constructs (1 mg, except for A3A 0.1 mg), together with plasmids required for rAAVLuc production. Virus production was assessed by transduction of
target cells and quantitation by luciferase assay. Panels below show immunoblots for APOBEC3 proteins (HA) in transfected cells and Ku86 as a
loading control. (D) Dose-response for A3A and the A3ApmlA3G chimera in the rAAV production assay. Panels below show immunoblots for
APOBEC3 (HA) and Ku86 proteins in transfected cells.
doi:10.1371/journal.ppat.1000439.g005
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localization or interference by the N-terminus (Figure S6). Thus
A3G-CT/KNLLCGFY provides the first gain-of-function mutant
for A3G and demonstrates that the VS1 region of A3A (residues
60 to 67) contributes to the antiviral activity against parvovirus.
Discussion
In this report we provide multiple pieces of evidence to show
that A3A inhibition of AAV can occur through a deaminase-
independent mechanism. Mutation of A3A active site residues that
are essential for catalytic activity (H70R, E72Q, SPC99-101AAA
and C106S) led to the loss of activity against AAV. However, other
mutants (F75L and mutants in VS1 and VS2) separated the
deaminase activity from the ability to inhibit AAV. Together these
data indicate that the integrity of the active site is important but
that deaminase activity is not required for AAV inhibition. In
APOBEC1, aromatic residues analogous to F75L and F95L of
A3A are required for both deaminase activity and binding to
nucleic acids [16,53]. In the case of A3A, we found that F95 is not
required for deaminase activity. This result probably reflects the
differences in structure and nucleic acid specificity between
APOBEC3 proteins and APOBEC1, as revealed by recent
structural studies [17,55]. We found that the F75L mutant was
deaminase-defective in our in vitro deaminase assay. The lack of
deaminase activity on a panel of target oligonucleotides demon-
strated that the F75L A3A mutant is truly deaminase-deficient,
and has not simply changed its target site preference and eluded
detection in the deaminase assay. Although the in vitro deaminase
assay has limitations, we demonstrated that lysates containing
F75L also lacked deaminase activity in the FRET assay [54].
Evidence that deaminase activity is not essential for inhibition of
AAV by A3A is consistent with the absence of signs of deamination
in AAV DNA in cells expressing A3A [14].
Deaminase-independent inhibition of DVif-HIV and retro-
elements by A3G has been controversial [35,39]. The deaminase-
defective A3G mutants in E259 retains anti-viral activity when
over-expressed [41,42]. However, when equivalent proteins levels
are compared in transient transfections or in stable cell lines, the
deaminase deficient mutant has significantly less potent antiviral
activity than wild-type A3G [38,46,61]. In our studies we assessed
the dose response of A3A mutants by comparing their antiviral
activity against AAV in titration experiments. We identified
deaminase-defective mutants (F75L and mutants in VS2) that
Figure 6. Mutants of A3A with residues replaced with the corresponding sequences of A3G. (A) Schematic of variable segments VS1 and
VS2, and the chimeric mutants generated for A3A in these regions. The VS1 segment corresponds to A3A residues 60 to 67, and VS2 corresponds to
A3A residues 132 to 137. (B) In vitro deamination assay. Proteins were immunoprecipitated from transfected cells and incubated with radiolabeled
oligonucleotide (T28CCCGT28) for 16 h in UDG-dependent assays. Arrows indicate the substrate and deaminated product. The panel below shows an
immunoblot to detect proteins in immunoprecipitates. (C) Production of rAAV in the presence of wild-type (0.1 mg) and mutant A3A proteins (1 mg).
Panels below show immunoblots for APOBEC3 proteins (HA) in transfected cells and Ku86 as a loading control.
doi:10.1371/journal.ppat.1000439.g006
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analyzed at comparable protein levels. In addition, the F75L and
VS2 mutants displayed the same subcellular localization as the
wild-type protein and thus their phenotype cannot be ascribed to
protein mislocalization.
In addition to providing evidence for deaminase-independent
antiviral activity, our study also offers insights into the structural
basis of APOBEC3 protein function. The linker and pseudoactive
site domains in the N-terminus of A3G are required for HIV-1
virion incorporation [19,62]. We demonstrate that these domains
also influence the target site specificity of APOBEC3. A3G prefers
the target site (T/C)CC [9,21,33,57,59], while A3A is more
flexible, showing preference for (T/C)CA [14]. Replacement of
the linker and pseudoactive sub-domains at the end of A3G with
those from A3A modified the target site preference towards the
A3A-specific consensus target TCA. Thus, A3A residues in the C-
terminus contribute to its target specificity, in agreement with data
from chimeric and mutant proteins of other APOBEC3 family
members [56]. Residues in the VS2 region have been implicated
in target site specificity [1], but in our hands the exchange of VS2
residues between A3A and A3G did not affect target specificity.
It is unclear why A3A has more potent in vitro deaminase activity
than other APOBEC3 proteins. Deaminase activity of A3G resides
in the C-terminal CDD [20,21,28,41,60], which shares 68%
identity with A3A. An intriguing difference between A3A and
A3G is the presence of two additional residues (WG) within the
PCX2–4C motif of A3A. Deletion of these amino acids in the
A3A/DWG mutant slightly reduced in vitro deaminase activity
(Figure 6). The variable region VS1 is situated immediately
upstream of the H-X-E-X23–28-P-C-X4-C conserved motif, and
replacement of A3A sequences with those from A3G caused a
decrease in deaminase activity. Substitution of the VS1 region in
A3G with sequences from A3A increased deaminase activity
compared to wild-type A3G (Figure S6). This suggests that the
VS1 region (residues 60–67) may contribute to the increased
enzymatic activity of A3A [14,50]. Interestingly, the VS1 region in
located in the active center loop 3 of the C-terminal domain of
A3G and disruption of this loop results in greatly impaired A3G
deaminase activity [55]. In the variable region VS2, substitution of
A3A amino acids with those from A3G also decreased deamina-
tion, suggesting that this region is important for catalytic activity.
This observation is supported by the decrease in deaminase
Figure 7. Identification of a gain-of-function mutant for A3G. (A) Schematic of full-length A3G and the C-terminal fragment A3G-CT. Chimeras
of A3G-CT were generated with variable segments VS1 and VS2 replaced with sequences of A3A. (B) Immunofluorescence to detect localization of
HA-tagged APOBEC3 and chimeric proteins (red) expressed by transfection in U2OS cells. Cell nuclei were detected by staining with DAPI (blue). (C)
Production of rAAV in the presence of APOBEC3 proteins. Virus production was assessed by transduction of target cells and quantitation by luciferase
assay. Immunoblots show similar expression levels for APOBEC proteins in transfected cells. Ku86 served as a loading control. The A3G-CT/KNLLCGFY
mutant demonstrated activity against AAV. The asterisks indicate that the inhibition with A3A and A3G-CT/KNLLCGFY was statistically significant
(p,0.001) when compared to mock by Student t test.
doi:10.1371/journal.ppat.1000439.g007
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A3G/YDPLYK) (Figure S6). Together these results indicate that
regions outside of the active site contribute to catalytic activity of
A3A. In support of our observations, a recent mutagenesis study of
A3G also suggested that C-terminal residues (residues 276–384)
are important for deaminase activity [60].
Multiple mechanisms have been proposed to explain the
deaminase-independent inhibition of retroelements and HBV by
APOBEC3G [35,39]. In the case of retroviruses, the APOBEC3
proteins have been suggested to inhibit RT, prevent accumulation
of reverse transcripts and viral cDNA in target cells, and block
integration [37,42,44,45]. Biochemical studies have shown that
purified recombinant A3G inhibited RT-catalyzed DNA elonga-
tion in vitro and this was independent of its deaminase activity [63].
A3G can inhibit HBV in the absence of extensive editing [12], and
has been suggested to be due to inhibition of early steps in viral
reverse transcription and strand elongation [48]. AAV inhibition
differs from these other systems because it does not involve an RT-
mediated step or any RNA substrates. Since A3A also inhibits
MVM replication and does not affect production of viral proteins
[14], we favor the idea that A3A inhibits parvovirus replication
through a direct interaction with the viral DNA or the replication
machinery. Binding to ssDNA by A3G is proposed to inhibit RT
processivity [21,63], and binding of A3A to ssDNA in the
parvovirus genome could physically block movement of the DNA
polymerase along the viral template. Although this inhibition
would be independent of catalytic activity, amino acids in the
active site may be required for efficient nucleic acid binding,
explaining the loss of antiviral activity for mutants such as E72Q
or C106S. Preliminary results suggest that the F75L mutant retains
its ability to bind nucleic acid (data not shown). Potential binding
sites could be the viral ITR or the ssDNA/dsDNA junction, which
may reduce Rep binding and inhibit DNA synthesis. A3A is not
found in high molecular weight complexes that have been
reported to modulate A3G activity [64,65], however we cannot
exclude the possibility that AAV inhibition might be mediated
through A3A interactions with AAV Rep or cellular proteins that
are required for AAV replication [66]. It will be interesting to
investigate whether recombinant A3A can block viral DNA
replication in an in vitro replication assay where we could test the
direct activity of A3A on AAV replication [67]. This approach,
however, is currently limited by the requirement for purified
recombinant A3A and its mutants.
Although 293 cells are a standard system used to study parvovirus
replication, it remains unclear whether endogenous A3A restricts
parvovirus infection in vivo. It is unknown which cells represent the
primary site of AAV infection and replication in vivo. It has been
shown that expression of APOBEC3 proteins is induced in response
to interferon-a (IFNa) [68]. The levels of A3A that achieve
inhibition of AAV in transfected cells are within the range of
endogenous A3A levels detected in peripheral blood mononuclear
cells (PBMCs) and macrophages activated with IFNa (Figure S7).
Therefore, it would be interesting to test whether cells refractory to
parvovirus replication will allow AAV replication when endogenous
A3A levels are reduced. In addition to parvoviruses, A3A is active
against LINE1 and other retrotransposons [14,50,51,64,69–71]
where hypermutation is not detected. It will be informative to
determinewhetherthis occurs bya mechanism similarto parvovirus
inhibition. In summary, our study demonstrates that the DNA
cytidine deaminase activity of A3A is not required for inhibition of
parvovirus replication. The combination of the single-domain
cytidine deaminase A3Awiththe simple model system of parvovirus
replication provides a valuable tool to uncover new mechanisms for
the antiviral activity of the APOBEC3 proteins.
Materials and Methods
Cell Lines
293T, HeLa, A9 and human osteosarcoma U2OS cell lines
were purchased from the American Tissue Culture Collection.
Cells were grown as monolayers in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum and
antibiotics at 37uC in a humid atmosphere containing 5% CO2.
Expression Plasmids
Expression plasmids encoding cDNAs for A3A (NM_145699)
and A3G (NM_021822) and the A3A mutants H70R, E72Q, and
C106S in the pcDNA3.1 (+) vector with a hemagglutinin (HA) tag
at the C-terminus have been previously described [14]. New A3A
and A3G mutants were generated by site-directed mutagenesis
using the QuikChange kit (Stratagene) (Table S1). The truncated
form of A3G (A3G-CT, residues 197-384) was generated by PCR
amplification of its C-terminus. Plasmids expressing AAV Rep/
Cap proteins (pXX2) and the adenovirus helper proteins (pXX6)
have been described [72]. The rAAV vector plasmid (pACLALuc)
consists of the luciferase gene amplified from pGL3basic
(Promega) cloned into an ITR-flanked expression cassette under
the control of the CMV promoter and the BGH polyadenylation
signal (pACLA). The complete ITR-flanked expression cassette in
pACLALuc is 4.3 Kb.
Production of Recombinant AAV
Recombinant AAV production assays were performed as
previously described [14,72]. Briefly, 293T cells were seeded at
0.5610
6 cells/well in 6-well plates and the next day were co-
transfected with pXX6 (2.25 mg), pXX2 (0.75 mg), pACLALuc
(0.75 mg) and APOBEC3 expression vector (1 mg unless otherwise
stated) or pcDNA3.1(+) control vector (1 mg). Dose-response
titrations maintained the total amount of effector DNA by
addition of pcDNA3.1(+). Transfections were performed in
duplicate or triplicate using polyethyleneimine (PEI) [73]. Cells
were harvested 72 h post-transfection after two washes in ice-cold
PBS, and one third of each sample was removed for immuno-
blotting. The other two thirds of the cells were used to generate
rAAVLuc virus lysates by freeze/thaw cycles followed by
centrifugation. Virus lysates were used to transduce 293T cells
in 48 wells in triplicate. Transduced cells were incubated with
Steady-Glo luciferase substrate reagent (Promega) 48 h post–
transduction and lucifierase activity was quantified in triplicate in
96 well Lumiplates (Greiner Bio-One) in a TopCount NXT
scintillation and luminescence counter (PerkinElmer). rAAV
production experiments are presented as mean+SEM of the
relative value (%) of at least three independent experiments, and
compared to mock transfections with pcDNA3.1(+).
Immunoblotting
Immunoblotting was performed essentially as described [14].
Cell pellets from rAAVLuc production assays were lysed in lysis
buffer (137 mM NaCl, 2.68 mM KCl, 10.1 mM Na2HPO4,
1.76 mM KH2PO4, 1 mM NaO3V, 20 mM b-glycerol phosphate,
20 mM NaF, 0.1% NP40, and 0.025% Triton-X 100) supple-
mented with Complete protease inhibitor cocktail (Roche) for
30 min on ice. The lysates were clarified by centrifugation at
10,0006g for 20 min. Protein concentrations from whole cell
lysates were quantified by BCA assay (Bio-Rad), and 20 mgo f
protein was loaded per well onto polyacrylamide gels. Proteins
were separated in 4–12% or 12% Acrylamide Bis-Tris NuPage
gels in MOPS buffer (Invitrogen) and transferred onto Hybond
nitrocellulose membranes (Amersham Biosciences). Membranes
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(Covance) and anti-Ku86 mAb (Santa Cruz). Bound antibody was
detected by incubation with goat anti-mouse antibody conjugated
to horseradish peroxidase (Jackson ImmunoResearch), and the
bands were visualized with enhanced chemiluminiscence reagent
(ECL Western Lightning Kit, PerkinElmer) followed by autoradi-
ography.
Immunofluorescence
APOBEC3 protein localization was determined by indirect
immunoflorescence [14]. U2OS or HeLa cells were grown on
glass coverslips in 24 well plates and transfected with 0.8 mg
APOBEC3 expression vector using Lipofectamine 2000 (Invitro-
gen). After 36–48 h, cells were washed with PBS, fixed with 3%
paraformaldehyde for 20 min and extracted with 0.5% Triton X-
100 in PBS for 10 min. Cells were incubated with 3% BSA for
30 min, followed by incubation with anti-HA mAb 16b12
(1:2000). A 1:2000 dilution of goat anti-mouse conjugated Alexa
Fluor 568 (Invitrogen) and DAPI (Sigma Aldrich) in 3% BSA in
PBS was added to cells and samples were incubated for 1 h at
room temperature. The coverslips were mounted in Fluoromount-
G (Southern Biotech) and cells were visualized by fluorescence
microscopy (Diaphot 300 inverted microscope, Nikon). For AAV
replication U2OS cells were seeded on glass coverslips and
transfected with APOBEC3 expression vector, and infected 16 h
post-transfection with wild-type AAV and/or adenovirus. After
24 hr, the cells were fixed and stained with anti-HA and anti-Rep
antibodies and DAPI as described above. Rep from the input virus
is undetectable in this assay, so positive Rep staining is indicative
of AAV replication.
Southern Blot Hybridization
Low molecular weight AAV episomal DNA was analyzed by
Southern hybridization with a
32P-labeled luciferase probe as
previously described [74]. Briefly, 293T cells grown in 6 well tissue
culture plates to 95% confluency were co-transfected with
plasmids for rAAV production using Lipofectamine 2000
following the manufacturer’s protocol. The following effector
plasmids were included: pcDNA3.1(+)( 1mg), A3G (1ug), A3A
(1 mg, 0.1 mg, 0.01 mg and 0.001 mg), F75L (1 mg) and F95L
(1 mg). After 48 h, the cells were collected and washed in PBS.
One third of each sample was removed for immunoblotting. DNA
was isolated from pellets by a modified HIRT protocol [74] and
digested with DpnI (New England Biolabs) to remove input
plasmid. DNA was processed by gel electrophoresis on a 1%
agarose gel in TAE buffer. The pACLALuc plasmid was digested
with SmaI as control. The gel was depurinated in 0.2 M HCl,
denatured in 1 M NaCl, 0.5 M NaOH, and neutralized in 0.5 M
Tris pH 7.5, 1.5 M NaCl. DNA was then transferred to a Hybond
XL membrane (Amersham Biosciences) and UV-cross linked. The
membrane was hybridized with a
32P labeled luciferase probe
generated by PCR using the primers described in Table S1 and
labeled with
32P dCTP using Radivue II labeling kit (Amersham),
and visualized in a FLA-5100 phosphorimager (Fuji).
Southern blot replication assays of wild-type MVM and MVM-
DBglII were performed as previously described [75].
In vitro Deaminase Assays
293T cells were seeded at 5610
5 cells/well in 6-well plates and
transfected after one day with 3 mg of APOBEC3 expression
vector. Two days post-transfection, the cells were rinsed twice with
cold PBS and lysed for 30 min on ice in lysis buffer (50 mM Tris,
pH 8.0, 40 mM KCl, 50 mM NaCl, 5 mM EDTA, 0.1% Triton
X-100, 10 mM DTT). Lysates were clarified by centrifugation at
13,0006g for 10 min and pre-cleared with 50 ml of High flow
protein-G-Sepharose (Amersham). The lysate was incubated with
anti-HA mAb 3F10 (Roche) for 2 h at 4uC. The lysate-antibody
was then incubated with High flow protein-G-Sepharose for 1-2 h
at 4uC. The resin was washed three times with lysis buffer. One-
fifth of the resin was removed for immunoblot analysis and the
remainder was washed once with deaminase reaction buffer
(40 mM Tris, pH 8.0, 10% glycerol, 40 mM KCl, 50 mM NaCl,
5 mM EDTA, and 1 mM DTT). PAGE purified deoxyoligonu-
cleotide (Table S1) was 59-end
32P labeled and added into 20 mlo f
deaminase reaction buffer. The reaction was incubated at 37uC for
20 h, stopped by heating to 90uC for 5 min, cooled on ice, and
then centrifuged to collect the resin at the bottom of tube. The
supernatant was incubated with uracil DNA glycosylase (New
England Biolabs) in buffer containing 20 mM Tris, pH 8.0, 1 mM
DTT for 1 h at 37uC and treated with 150 mM NaOH for 1 h at
37uC. The samples were incubated at 95uC for 5 min, 4uC for
2 min and separated by 15% TBE/urea-PAGE. The gel was
dried, exposed to a phosphorimager screen and analyzed using a
FLA-5100 scanner (Fuji).
For in vitro synthesis of A3A and mutants we employed the TNT
Coupled Wheat Germ Extract System (Promega) using T7
polymerase. Translation reactions were performed with non-
labeled amino acids following the manufacturer’s protocol in 50 ml
final volume that included 1 mg of pcDNA3.1(+) plasmid encoding
APOBEC3. Reactions were incubated for 90 min at 30uC. After
incubation, 450 ml of TritonX-100 buffer (50 mM Tris, pH 8.0,
40 mM KCl, 50 mM NaCl, 5 mM EDTA, 0.1% Triton X-100,
10 mM DTT) were added to the reactions and used to analyze
deaminase activity after immunoprecipitation as described above.
In order to measure deaminase activity directly from IVT
reactions, after 90 min incubation at 30uC translation reactions
were centrifuged at 10,0006g for 1 min. An aliquot of supernatant
(5 ml) was removed for immunoblot analysis. The reaction mixture
(15 ml of supernatant) was incubated with 59-end
32P labeled
deoxyoligonucleotide in 30 ml of deaminase reaction buffer and
assayed for deaminase activity following the same procedure
described above.
FRET-Based Deaminase Activity Assay from Cell Lysates
To quantify deaminase activity from cell lysates, we used a
modification of the FRET-based protocol described by Thielen et
al. [54]. 293T cells were seeded at 1610
6 cells/well in 6 cm plates
and a day later transfected with 8 mg of APOBEC3 expression
vector. After 36 to 48 h, cells were resuspended in lysis buffer
(200 ml) and lysates were obtained as described above. Cell lysate
(10 ml) was mixed with 70 ml of FRET deaminase buffer (40 mM
Tris, pH 8.0, 40 mM KCl, 50 mM NaCl, 5 mM EDTA)
containing 10 pmol of dual-labeled probe (Table S1) and 0.4 units
of UDG (New England Biolabs). Reactions were incubated at
37uC for 90 min followed by addition of 4 ml of 4N NaOH and
incubation at 37uC for 30 min. Reactions were neutralized with
4 ml of 4N HCl and 36 ml of 1 M Tris-HCl (pH 8). 6FAM
fluorescence was measured at 25uC in an Mx30005P (Stratagene).
Two-fold serial dilutions of each lysate were analyzed in duplicate.
Fluorescence detected in 293T cells transfected with pcDNA3.1
(mock) was substracted from all samples and deaminase activity is
shown as relative fluorescence units (RFU).
Detection of Endogenous A3A
Human monocytes were purified from leukocyte enriched blood
samples (New York Blood Center) using CD14+ magnetic beads
(Miltenyi Biotec) according to manufacturer instructions. The
CD14
+ monocytes were cultured with 50 ng/ml GM-CSF
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macrophages. The monocyte-derived macrophages were plated
in 12 well plates at 10
6 cells per well and cultured with or without
2000U of Universal Type I Interferon (PBL Biomedical Labora-
tories) for 20 hours. The cells were then collected in lysis buffer.
Cell lysates from human peripheral blood mononuclear cells
(PBMCs) were obtained from F. Chisari (The Scripps Research
Institute) [76]. PBMCs were treated with 1000U of IFN-a or kept
untreated for 24 hrs before cell lysates were generated. Lysates of
PBMCs (60 mg) and macrophages (30 mg) of each sample were run
on 4–12% or 12% Bis-Tris gels and analyzed by immunoblotting
as described above. Anti-A3A (raised against an N-terminal
peptide) (1:250 dilution) or anti-recombinant A3A (1:1000
dilution) polyclonal rabbit sera were used for A3A detection as
described.
Supporting Information
Figure S1 APOBEC3A proteins synthesized from coupled in-
vitro transcription-translation are active in UDG-dependent
deaminase assays. Deaminase activity of A3A and mutant proteins
generated by cell transfection and in-vitro coupled transcription-
translation (IVT) was analyzed in UDG-dependent deaminase
assays. (A) 293T cells were transfected with plasmids for A3A and
mutants. Cells were harvested at 48 hrs post-transfection, and
lysates were subject to immunoprecipitation (IP) with anti-HA
antibody (3F10). 4/5 of the IP was incubated with a 59-end
32P
labeled T28TCAT28 deoxyoligonucleotide and tested in UDG-
dependent deaminase assays. Arrows indicate substrate deoxyoli-
gonucleotide and cleaved deaminated product. Bottom panel
shows an immunoblot corresponding to 1/5 of the IP analyzed
with an anti-HA antibody (16B12). Asterisks indicate bands
corresponding to IgG light chain. A3A truncations are: TruncA
(aa 1–145), TruncB (aa 1–165), and TruncC (aa 53–199). (B) Wild-
type and mutant A3A proteins were synthesized by IVT as
described in Methods. pcDNA3.1(+) was included in IVTs as
mock. A3A proteins were immunoprecipitated with 3F10 antibody
and tested in the UDG-dependent deaminase assay. Immunopre-
cipitated A3A from transfected cells was included as a control.
Middle panel shows 1/5 of the IP protein analyzed by
immunoblotting with 16B12 antibody. Bottom panel shows
immunoblotting of lysates to demonstrate that equal amounts of
protein were generated by IVT. (C) Wild-type and mutant A3A
proteins were tested directly from IVT reactions for deaminase
activity. Bottom panel shows an immunoblot of 1/5 of the IVT-
synthesized proteins loaded into the deaminase reactions.
Found at: doi:10.1371/journal.ppat.1000439.s001 (1.92 MB PDF)
Figure S2 Lack of deaminase activity for F75L is not due to
modified target sequence preference and is supported by the lack
of deamination measured by FRET. (A) To rule out differences in
target sequence preference, A3A and F75L were tested in UDG-
dependent deaminase assays against 16 different target sites (Table
S1). Target sequence preference of A3A and F75L was determined
on a panel of four
32P-labeled deoxyoligonucleotide substrates,
each containing four target sites. The -1 base is shown at the top of
each lane and the +1 base is shown on the left. The structure of the
cleaved products is shown on the right. (B) Quantification of
deaminase acitivity by FRET in cell lysates obtained from 293T
cells transfected with A3A, E72Q, F75L, F95L and C106S. Cell
lysates were incubated with a dual-labeled probe containing the
CCCG target sequence (Table S1). The TAMRA fluorophore
quenches emission by the 6FAM fluorophore. After deamination
and treatment with UDG and high pH, 6FAM fluorescence
emission can be detected from the cleaved probe. Two-fold serial
dilutions of each lysate were analyzed by duplicate and
represented as mean6SEM. Results show that deaminase activity
is detected in cell lysates obtained from cells transfected with A3A
and F95L, while deaminase activity of E72Q, F75L and C106S is
not distinguishable from the background level. Bottom panel
shows an immunoblot of cell lysates.
Found at: doi:10.1371/journal.ppat.1000439.s002 (2.23 MB PDF)
Figure S3 Localization of A3A/A3G chimeras. Immunofluo-
rescence to detect localization of HA-tagged APOBEC3 and
chimeric proteins (red) expressed by transfection in U2OS cells.
Cell nuclei were detected by staining with DAPI (blue). (A)
Localization of wild-type APOBEC3 proteins and A3A/A3G
chimeras. (B) Localization of A3A mutants with sequences
incorporated from A3G.
Found at: doi:10.1371/journal.ppat.1000439.s003 (9.29 MB PDF)
Figure S4 Inhibition of rAAV production by A3A/A3G
chimeras in the VS1 region. Dose-response for A3A and mutant
proteins in the rAAV production assay. Virus production was
assessed by transduction of target cells and quantitation by
luciferase assay. Panels below show immunoblots for APOBEC3
(HA) and Ku86 proteins in transfected cells.
Found at: doi:10.1371/journal.ppat.1000439.s004 (0.39 MB PDF)
Figure S5 Dose-response antiviral activity of A3G-CT/
KNLLCGFY. Comparison of A3A and A3G-CT/KNLLCGFY
antiviral activity over a dose-response in rAAV production assays.
Comparable levels of A3A and A3G-CT/KNLLCGFY resulted in
,95% and ,50% inhibition respectively. Bottom panels show
immunoblots for A3A and A3G-CT/KNLLCGFY (HA), and
Ku86 protein as a loading control. The asterisks indicate that the
inhibition with A3G-CT/KNLLCGFY was statistically significant
(p,0.001) when compared to mock by Student t test.
Found at: doi:10.1371/journal.ppat.1000439.s005 (0.53 MB PDF)
Figure S6 Chimeric A3G proteins with sequences replaced with
VS1 and VS2 from A3A. (A) Immunofluorescence to detect
localization of HA-tagged APOBEC3 and chimeric proteins (red)
expressed by transfection in U2OS cells. Cell nuclei were detected
by staining with DAPI (blue). (B) In vitro deamination assay.
Proteins were immunoprecipitated from transfected cells and
incubated with the radiolabeled substrate in the standard assay.
Arrows indicate the substrate and deaminated product. The panel
below shows an immunoblot to detect proteins in immunoprecip-
itates. Arrows indicate bands corresponding to APOBEC3
proteins. Asterisk indicates bands corresponding to IgG light
chain. (C) Production of rAAV in the presence of APOBEC3
proteins. Virus production was assessed by transduction of target
cells and quantitation by luciferase assay. Immunoblots show
similar expression levels for APOBEC3 proteins (HA) in
transfected cells. Ku86 served as a loading control.
Found at: doi:10.1371/journal.ppat.1000439.s006 (3.93 MB PDF)
Figure S7 Antiviral activity of A3A is achieved with physiolog-
ical levels of transfected A3A. (A) Antiviral activity of A3A was
analyzed in a rAAVLuc production experiment over a dose
response. Expression levels of A3A were analyzed by immuno-
blotting using an anti-HA antibody (top blot), and compared to
endogenous levels of A3A expressed in human PBMCs incubated
with IFNa. A3A was detected using a rabbit polyclonal antisera
raised against an N-terminal A3A specific peptide (bottom blot).
Arrow indicates bands corresponding to A3A. Background band
below A3A is indicated with an asterisk. (B) In panel B the
expression levels of A3A are compared to endogenous levels of
A3A induced in human macrophages in response to IFNa. A3A
Deaminase-Independent APOBEC3A Antiviral Activity
PLoS Pathogens | www.plospathogens.org 12 May 2009 | Volume 5 | Issue 5 | e1000439was detected with polyclonal rabbit serum generated to recombi-
nant A3A protein.
Found at: doi:10.1371/journal.ppat.1000439.s007 (1.09 MB PDF)
Table S1 Oligonucleotides used in this study. Sequences
corresponding to the oligonucleotides used in this study. Name,
template and type of experiments are indicated for each
oligonucleotide. D.A. (deaminase assays). N/A (not applicable).
Found at: doi:10.1371/journal.ppat.1000439.s008 (0.08 MB
DOC)
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